The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients. The Food and Drug Administration (FDA) has approved ...

MAVYRET The FDA has approved Mavyret (glecaprevir and pibrentasvir; AbbVie) for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg. The Food ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mavyret demonstrated 97% sustained virologic response in ...

AbbVie has received the Food and Drug Administration’s nod for a new indication for Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ...

AbbVie’s hepatitis C blockbuster Mavyret could soon also be an eight-week treatment for patients with compensated cirrhosis, thanks to positive new phase 3b data. That would give it more firepower as ...

Please provide your email address to receive an email when new articles are posted on . The approval allows for immediate treatment following diagnosis. Patients treated in a phase 3 study experienced ...

AbbVie, Inc. ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, ...

HCV is a curable condition, but patients can often go undiagnosed. 1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as ...

AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret. Its TV ads emphasize a cure “in only 8 weeks,” with actors who portray patients repeating the phrase as they ...

U.S. regulators have approved the first drug to treat all forms of hepatitis C in as little as eight weeks. The pill combination from AbbVie Inc. was approved Thursday by the Food and Drug ...